Prevalence of Human Leukocyte Antigen HLA-B*5701 in HIV-1 Infected Individuals in Brazil

DOI: 10.4236/ojgen.2014.41008   PDF   HTML     3,927 Downloads   5,534 Views   Citations


This study was designed to establish the prevalence of HLA-B*5701 at HIV-1 infected individuals in Brazil. A total of 517 consecutive individuals were followed in this study from February 2009 through July 2011. The presence of HLA-B*5701 was determined by Nested-PCR with HLA-B*57 and HLA-B*5701 sequence-specific primers (PCR-SSP). The expression of HLA-B*57 was negative in the 385 (74.5%) and positive in the 103 (19.9%) of infected individuals. Among these, the expression of HLA-B5701 was positive in the 29 (5.6%) of individuals. No demographic or ethnic differences were found between HLA-B*57/HLA-B*5701 HIV-1 negative patients, with a prevalence of Caucasians (57.1%) individuals. During the period of study, 68 patients were submited to an abacavir contain- ing regimen. The HLA-B*5701 allele was observed in 7 (10.3%) patients, with a significant incidence of Hypersensitivity reactions at 4 of them (p < 0.001). Conclusions: Although Brazilian population consists of a mixture of individuals of Caucasian, African and Native American genetic background, prevalence of HLA-B*5701 in this population is similar to the one found in pure Caucasians.

Share and Cite:

Araújo, C. , Carvalho, C. , Souza Freire, M. , Yamaguti, A. , Scaff, I. , Souza, F. , Silvestre Silva, F. , Diaz, R. and Guerreiro da Silva, I. (2014) Prevalence of Human Leukocyte Antigen HLA-B*5701 in HIV-1 Infected Individuals in Brazil. Open Journal of Genetics, 4, 56-62. doi: 10.4236/ojgen.2014.41008.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Demoly, P. and Gomes, E.R. (2005) Drug Hypersensitivities: Definition Epidemiology and Risk Factors. Allergy and Immunology, 37, 202-206.
[2] Carr, A. and Cooper, D.A. (2000) Adverse Effects of Antiretroviral Therapy. Lancet, 356, 1423-1430.
[3] Pirmohamed, M. and Back, D.J. (2001) The Pharmacogenomics of HIV Therapy. The Pharmacogenomics Journal, 1, 243-253.
[4] Vidal, F., Gutiérrez, F., Gutiérrez, M., Olona, M., Sánchez, V., Mateo, G., et al. (2010) Pharmacogenetics of Adverse Effects Due to Antiretroviral Drugs. AIDS, 12, 15-30.
[5] Mallal, S., Phillips, E., Carosi, G., Molina, J.M., Workman, C., Tomazic, J., et al. (2008) HLA B*5701 Screening for Hypersensitivity to Abacavir. The New England Journal of Medicine, 358, 568-579.
[6] Young, B., Squires, K., Patel, P., Dejesus, E., Bellos, N., Berger, D., et al. (2008) First Large, Multicenter, Open-Label Study Utilizing HLA-B*5701 Screening for Abacavir Hypersensitivity in North America. AIDS, 20, 1673-1675.
[7] Park, W.B., Choe, P.G., Song, K.H., Lee, S., Jang, H.C., Jeon, J.H., et al. (2009) Should HLA-B*5701 Screening Be Performed in Every Ethnic Group before Starting Abacavir? HIV/AIDS, 48, 365-367.
[8] Martin, A., Nolan, D., Gaudieri, S., Almeida, C.A., Nolan, R., James, I., et al. (2004) Predisposition to Abacavir Hypersensitivity Conferred by HLA-B*5701 and a Haplotypic Hsp70-Hom Variant. Proceedings of the National Academy of Sciences of the United States of America, 101, 4180-4185.
[9] Martin, A.M., Nolan, D. and Mallal, S. (2005) HLA-B*5701 Typing by Sequence-Specific Amplification: Validation and Comparison with Sequence-Based Typing. Tissue Antigens, 65, 571-574.
[10] Pirmohamed, M. (2006) Genetic Factors in the Predisposition to Drug-Induced Hypersensitivy Reactions. AAPS Journals, 8, E20-E26.
[11] Hughes, C.A., Foisy, M.M., Dewhurst, N., Higgins, N., Robinson, L., Kelly, D.V., et al. (2008) Abacavir Hypersensitivity Reaction: An Update. Annals of Pharmacotherapy, 42, 387-396.
[12] Lucas, A., Nolan, D. and Mallal, S. (2007) HLA-B*5701 Screening for Susceptibility to Abacavir Hypersensitivity. Journal of Antimicrobial Chemotherapy, 59, 591-593.
[13] Phillips, E.J. (2006) Genetic Screening to Prevent Abacavir Hypersensitivity Reaction: Are We There Yet. Clinical Infectious Diseases, 43, 103-105.
[14] Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A.M., Moore, C., et al. (2002) Association between Presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir. Lancet, 359, 727-732.
[15] Phillips, E., Rauch, A., Nolan, D., Martin, A., Almeida, C., Knowles, S., et al. (2007) Genetic Characterization of Patients with MHC Class I Mediated Abacavir Hypersensitivity Reaction. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 22-25 July 2007, Abstract No. MOPEB001.
[16] Phillips, E.J., Wong, G.A., Kaul, R., Shahabi, K., Nolan, D.A., Knowles, S.R., et al. (2005) Clinical and Immunogenetic Correlates of Abacavir Hypersensitivity. AIDS, 19, 979-981.
[17] Parczewski, M., Leszczyszyn-Pynka, M., Wnuk, A., Urbañska, A., Fuksiñska, K., Bander, D., et al. (2010) Introduction of Pharmacogenetic Screening for the Human Leucocyte Antigen (HLA) B*5701 Variant in Polish HIV-Infected Patients. HIV Medicine, 11, 345-348.
[18] Waters, L.J., Mandalia, S., Gazzard, B. and Nelson, M. (2007) Prospective HLA-B*5701 Screening and Abacavir Hypersensitivity: A Single Centre Experience. AIDS, 21, 2533-2549.
[19] Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C. and Mallal, S. (2006) Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity Reactions in the Western Australian HIV Cohort Study. Clinical Infectious Diseases, 43, 99-102.
[20] Zucman, D., Truchis, P., Majerholc, C., Stegman, S. and Caillat-Zucman, S. (2007) Prospective Screening for Human Leukocyte Antigen-B*5701 Avoids Abacavir Hypersensitivity Reaction in the Ethnically Mixed French HIV Population. Journal of Acquired Immune Deficiency Syndromes, 45, 1-3.
[21] Hammond, E., Mamotte, C., Nolan, D. and Mallal, S. (2007) HLA-B*5701 Typing: Evaluation of an Allele-Specific Polymerase Chain Reaction Melting Assay. Tissue Antigens, 70, 58-61.
[22] Saag, M., Balu, R., Phillips, E., Brachman, P., Martorell, C., Burman, W., et al. (2008) High Sensitivity of Human Leukocyte Antigen-b*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients. Clinical Infectious Diseases, 46, 1111-1118.
[23] Sun, H.Y., Hung, C.C., Lin, P.H., Chang, S.F., Yang, C.Y., Chang, S.Y., et al. (2007) Incidence of Abacavir Hypersensitivity and Its Relationship with HLA-B*5701 in HIV-Infected Patients in Taiwan. Journal of Antimicrobial Chemotherapy, 60, 599-604.
[24] Hughes, S., Parry-Billingsc, K., Givens, N., Wong, D., Loeschel, E., Parada, P., et al. (2006) Genetic Screening Test for Abacavir Hypersensitivity—PREDICT-1: Description of a Novel Randomised Prospective Study Design to Determine the Clinical Utility of Prognostic Screening for HLA-B*5701 in 8th International Congress Drug Therapy in HIV Infection. Glaugow, Scotland UK.
[25] Orkin, C., Wang, J., Bergin, C., Molina, J.M., Lazzarin, A., Cavassini, M., et al. (2010) An Epidemiologic Study to Determine the Prevalence of the HLA-B*5701 Allele among HIV-Positive Patients in Europe. Pharmacogenetics and Genomics, 20, 307-314.
[26] Bonilla, C., et al. (2004) Admixture in the Hispanics of the San Luis Valley, Colorado, and Its Implications for Complex Trait Gene Mapping. Annals of Human Genetics, 68, 139-153.
[27] Luizon, M.R., et al. (2008) Ancestry Informative Markers in Amerindians from Brazilian Amazon. American Journal of Human Biology, 20, 86-90.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.